Why the study?
Does TAVR+PCI improve short- and long-term outcomes compared to SAVR+CABG in heart failure patients with concomitant aortic stenosis and coronary artery disease?
Cohort (n=1,246)
Does TAVR+PCI improve short- and long-term outcomes compared to SAVR+CABG in heart failure patients with concomitant aortic stenosis and coronary artery disease?
Answers are grounded in this paper and cite their sources.
In heart failure patients with aortic stenosis and coronary artery disease, TAVR+PCI is associated with better short-term outcomes, but SAVR+CABG provides superior long-term survival and freedom from MACE at 5 years.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
El-Zein et al. (2026) conducted a cohort in Heart failure with concomitant aortic stenosis and coronary artery disease (n=1,246). TAVR+PCI vs. SAVR+CABG was evaluated on 5-year mortality (RR 0.68, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: